Hamburg, Germany, October 15th, 2024 – Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, in patients with celiac disease. The study data serves as the first clinical proof of concept for Topas' proprietary nanoparticle platform and its potential to induce targeted, antigen-specific tolerogenic effects.

Schlieren / Zurich, Switzerland, 27 August, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces that Alex Bastian has joined the Company as VP Commercial Strategy.

Munich, Germany, July 16, 2024 – CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion's Growth Opportunities Fund ("Forbion Growth"), Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon Capital Partners, Novartis Venture Fund and Vesalius Biocapital III also participated in the round.

Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors.

Munich, Germany, June 2, 2024 – CatalYm today announced positive new follow-up results from its ongoing "GDFATHER" Phase 1/2a trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 1/2a) (NCT04725474) in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago.

Schlieren / Zurich, Switzerland, 7^th May, 2024 – Memo Therapeutics AG (or "MTx") today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.

Amsterdam, the Netherlands, April 30, 2024 – Scenic Biotech today announced that it has entered into a research collaboration with Bristol Myers Squibb (NYSE: BMY) to accelerate the development of Bristol Myers Squibb's drug targets by identifying target biology for indication selection and expansion.

Munich, February, 29^th 2024 – Munich based Mecuris GmbH and Ottobock SE & Co. KGaA agreed on the transfer of technology for the creation of individualized O&P devices. The software developed for the Mecuris Solution Platform enables orthopaedic technicians to design and build customized 3D-printed prosthetic- and orthotic-products.

Diepenbeek, Belgium, February 21st, 2024 – Rejuvenate Biomed NV ("Rejuvenate Biomed"), a pioneering clinical-stage platform and pipeline company committed to enhancing lifelong health through innovative therapeutics, today announces breakthrough functional outcome results from its Phase 1b trial of lead candidate RJx-01 for the treatment of sarcopenia.

SAN FRANCISCO, February 16, 2024 – Caresyntax, a pioneer in surgical intelligence and automation technologies, is excited to announce its recognition as one of the Fierce Healthcare's Fierce 15 of 2024, a prestigious acknowledgment of the most innovative healthcare companies across the United States.